Bayer Schering Pharma Ag

Bayer Healthcare LLC

Kirk McLean

David Richard Light

Haiyan Jiang

Glenn Pierce

Richard L Feldman

Xiao-Yan Zhao

Ji-Yun Kim

Junliang Pan

James Wu

David Bruce Light

Renate Parry

Douglas W Schneider

Noboru Satozawa

Tara Renee Heitner Hansen

Marian Seto

Targeted coagulation factors comprising a coagulation factor linked with at least one domain that specifically binds to a membrane protein on a blood cell is provided. The disclosed targeted coagulation factors increase the efficiency of coagulation factors and prolong their duration of action and thus, are an improvement for the treatment of hematological diseases such as hemophilia A.

Targeted coagulation factors and method of using the same

Dimeric molecular complexes useful for diagnostics and therapeutics.

Dimeric molecular complexes

This invention relates to novel antibodies that bind with greater affinity to the factor VIIa/tissue factor (FVIIa/TF) complex than to tissue factor (TF) alone, do not compete for binding to TF with FVII and FX, an inhibit FX activation. The antibodies bind at the site of injury and prevent the initiation of thrombosis. The antibodies can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.

Polynucleotides encoding anticoagulant antibodies

This invention relates to novel fusion proteins which are comprised of a targeting protein that binds tissue factor (TF), which is operably linked to the thrombomodulin (TM) EGF456 domain alone or in combination with at least one other TM domain selected from the group consisting of the N-terminal hydrophobic region domain, the EGF123 domain, the interdomain loop between EGF3 and EGF4, and the O-glycosylated Ser/Thr-rich domain, or analogs, fragments, derivatives or variants thereof. The fusion protein binds at the site of injury and prevents the initiation of thrombosis. The fusion protein can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.

Methods of using novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants

Polynucleotides encoding anticoagulant fusion proteins

Tissue factor targeted antibodies as anticoagulants

Tissue factor targeted thrombomodulin fusion proteins as anticoagulants

Growing community of inventors

Oakland, CA, United States of America

Kirk McLean